Skip to main content
. 2020 Mar 4;5(2):e00875-19. doi: 10.1128/mSphere.00875-19

TABLE 1.

Donor and recipient strains with their resistance profiles and antibiotic selection used for culture overnight before the conjugation assay

Donor or recipient strain Resistance profilea
E. coli UB5201 NAL
E. coli UB5201 SGI1-LK1 NAL, AMP, CHL, KAN, GEN, STR, SUL, TMP, TET
E. coli UB5201/pEA409TEM24 NAL, AMP, SAM, CAZ, KAN, AMK, STR, SUL, TMP
E. coli UB1637rif RIF
E. coli UB1637rif SGI1-LK1 RIF, AMP, CHL, KAN, GEN, STR, SUL, TMP, TET
E. coli UB1637rif SGI1-LK1/pEA409TEM24 RIF, AMP, CAZ, CHL, KAN, GEN, AMK, STR, SUL, TMP, TET
P. mirabilis Pm294MATLI(SGI1-LK1) AMX, CHL, KAN, GEN, SPT, STR, SUL, TMP, TET
P. mirabilis Pm294MATLI(SGI1-LK1)/pEA409TEM24 AMP, SAM, CAZ, CHL, KAN, GEN, AMK, STR, SUL, TMP, TET
a

Antimicrobial resistance conferred by pEA409TEM24 or SGI1-LK1 is shown in boldface type. Antimicrobial susceptibility tests were performed in accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines except for the P. mirabilis Pm294MATLI(SGI1-LK1) strain, which was previously tested in accordance with the guidelines of the French Committee on Antimicrobial Susceptibility/European Committee on Antimicrobial Susceptibility Testing (CA-SFM/EUCAST). The underlined antibiotics were used to keep the pEA409TEM24 plasmid and SGI1-LK1 and to select the strain. NAL, nalidixic acid; AMP, ampicillin; CHL, chloramphenicol; KAN, kanamycin; GEN, gentamycin; STR, streptomycin; SUL, sulbactam; TMP, trimethoprim; TET, tetracycline; SAM, ampicillin-sulbactam; CAZ, ceftazidime; AMK, amikacin; RIF, rifampin; AMX, amoxicillin; SPT, spectinomycin.